Aletha Y Akers1, Caren Steinway, Sarita Sonalkar, Lisa K Perriera, Courtney Schreiber, Jennifer Harding, J Felipe Garcia-Espana. 1. Craig Dalsimer Division of Adolescent Medicine, Children's Hospital of Philadelphia, Children's Hospital of Philadelphia Research Institute, PolicyLab, Roberts Center for Pediatric Research, the Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, and the Department of Obstetrics and Gynecology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Abstract
OBJECTIVE: To estimate the effect of a 1% lidocaine paracervical nerve block on pain during intrauterine device (IUD) insertion compared with a sham block in adolescents and young women. METHODS: We conducted a multisite, single-blind, sham-controlled randomized trial in adolescents and young women having a 13.5-mg levonorgestrel IUD inserted. Enrollment occurred at three family planning clinics in Philadelphia, Pennsylvania. Eligible adolescents and young women were aged 14-22 years, nulliparous, not currently or recently pregnant, and English-speaking. Participants were randomized using computer-generated allocation in block sizes of four to receive a 10-mL 1% lidocaine paracervical block or a sham block (1 cm depression of the vaginal epithelium at paracervical block sites with a wooden cotton-tipped applicator). Only patients were blinded. The primary outcome was pain after IUD insertion measured with a 100-mm visual analog scale. Using a two-sided t test and assuming a 20-mm difference in visual analog scale scores, a SD of 28 mm, an α of 0.05, and 90% power, a sample of 43 participants per group was estimated. RESULTS:Between March 2015 and July 2016, 95 participants enrolled (47 lidocaine block group; 48 sham block group). All were included in the analysis. Forty-four percent were white, 36% black, 65% privately insured, and 79% previously used contraception. The median visual analog scale score after IUD insertion was 30.0 (95% CI 20.0-58.0) in the lidocaine block group and 71.5 (95% CI 66.0-82.0) in the sham block (P<.001). CONCLUSION: A 10-mL 1% lidocaine paracervical nerve block reduces pain during IUD insertion in adolescents and young women compared with a sham block with pressure on the vaginal epithelium. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02352714.
RCT Entities:
OBJECTIVE: To estimate the effect of a 1% lidocaine paracervical nerve block on pain during intrauterine device (IUD) insertion compared with a sham block in adolescents and young women. METHODS: We conducted a multisite, single-blind, sham-controlled randomized trial in adolescents and young women having a 13.5-mg levonorgestrel IUD inserted. Enrollment occurred at three family planning clinics in Philadelphia, Pennsylvania. Eligible adolescents and young women were aged 14-22 years, nulliparous, not currently or recently pregnant, and English-speaking. Participants were randomized using computer-generated allocation in block sizes of four to receive a 10-mL 1% lidocaineparacervical block or a sham block (1 cm depression of the vaginal epithelium at paracervical block sites with a wooden cotton-tipped applicator). Only patients were blinded. The primary outcome was pain after IUD insertion measured with a 100-mm visual analog scale. Using a two-sided t test and assuming a 20-mm difference in visual analog scale scores, a SD of 28 mm, an α of 0.05, and 90% power, a sample of 43 participants per group was estimated. RESULTS: Between March 2015 and July 2016, 95 participants enrolled (47 lidocaine block group; 48 sham block group). All were included in the analysis. Forty-four percent were white, 36% black, 65% privately insured, and 79% previously used contraception. The median visual analog scale score after IUD insertion was 30.0 (95% CI 20.0-58.0) in the lidocaine block group and 71.5 (95% CI 66.0-82.0) in the sham block (P<.001). CONCLUSION: A 10-mL 1% lidocaine paracervical nerve block reduces pain during IUD insertion in adolescents and young women compared with a sham block with pressure on the vaginal epithelium. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02352714.
Authors: Tegan A Hunter; Sarita Sonalkar; Courtney A Schreiber; Lisa K Perriera; Mary D Sammel; Aletha Y Akers Journal: J Pediatr Adolesc Gynecol Date: 2019-09-26 Impact factor: 1.814
Authors: Katherine L O'Flynn O'Brien; Aletha Y Akers; Lisa K Perriera; Courtney A Schreiber; J Felipe Garcia-Espana; Sarita Sonalkar Journal: J Pediatr Adolesc Gynecol Date: 2019-01-08 Impact factor: 1.814
Authors: Aletha Y Akers; Jennifer Harding; Lisa K Perriera; Courtney Schreiber; J Felipe Garcia-Espana; Sarita Sonalkar Journal: Obstet Gynecol Date: 2018-06 Impact factor: 7.661
Authors: Elisabeth Maritschnegg; Florian Heitz; Nina Pecha; Jirí Bouda; Fabian Trillsch; Christoph Grimm; Adriaan Vanderstichele; Christiane Agreiter; Philipp Harter; Eva Obermayr; Ignace Vergote; Robert Zeillinger; Paul Speiser Journal: Int J Gynecol Cancer Date: 2018-11 Impact factor: 3.437